Recently rebranded SV Health Investors said this week it closed its 6th flagship fund at $400 million.

The new SV VI fund will follow suit with previous funds and be multi-sector focused, the group said.

The fund will look to invest in early-stage opportunities in biotechnology, early-stage and revenue-stage opportunities in medical devices and growth equity opportunities in healthcare services and digital health companies.

“It’s exciting to continue applying our team’s expertise, networks and operating experience for entrepreneurs and companies that have the potential to develop and advance important new treatments and solutions. We are backing remarkable entrepreneurs and proven operating executives who are helping transform healthcare and improve patients’ lives,” managing partner Paul LaViolette said in a prepared statement.

SV Health Investors said it also manages the Dementia Discovery fund and 5 others, with capital commitments of more than $2 billion, all of which aim to support entrepreneurs and companies looking to create innovative treatments and healthcare solutions.

“We’re grateful for the support for SV VI from our limited partners — both our longstanding investors and the new LPs we’re welcoming. We appreciate the enthusiasm they have expressed and demonstrated for our proven, diversified strategy within healthcare and for our team, both the veterans and those who have joined us relatively recently,” chair Gene Hill said in a press release.

Yesterday, the group announced that it had rebranded from its previous name, SV Life Sciences, to SV Health Investors.

The Boston-based investment group said the new moniker will “better reflect the firm’s longstanding strategy and multi-sector focus.”